![](https://svhealth.ams3.digitaloceanspaces.com/1.-Impact-report.png)
2024 SV Therapeutics Impact & ESG Report
Read More
![](https://svhealth.ams3.digitaloceanspaces.com/Alpheus-Medical-Final-Colors-tinted.png)
Alpheus Medical Announces Positive Phase 1/2 Trial Results for the Treatment of Recurrent High-Grade Gliomas
![](https://svhealth.ams3.digitaloceanspaces.com/logos/csa-medical-logo.jpg)
Data Presented at the American College of Chest Physicians Correlates Airway Remodeling with Positive Clinical Outcomes Utilizing the RejuvenAir® System
![](https://svhealth.ams3.digitaloceanspaces.com/SpectraWAVE-Color-Logo.png)
SpectraWAVE Announces $50M Series B Financing to Drive Commercial Expansion and Product Additions to the HyperVue™ Imaging System
![](https://svhealth.ams3.digitaloceanspaces.com/Pulse-Biosciences.png)
Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors - Paul LaViolette to serve as Co-Chairman alongside Robert W. Duggan, adding 40 years of medical technology development, operating and leadership expertise
![](https://svhealth.ams3.digitaloceanspaces.com/Spineology-Logo-3-Dark-Blue-Light-Blue-Sparky.png)
Spineology® Announces $25 Million Equity Financing – Funding to aid in acceleration of commercial growth, clinical education programs, and product development enhancements for highly-differentiated OptiMesh® implant portfolio –
![](https://svhealth.ams3.digitaloceanspaces.com/Entronix-SV_2024-08-09-091637_fqqf.jpg)
Edwards Lifesciences Expands Structural Heart Portfolio With Acquisitions of JenaValve and Endotronix
![](https://svhealth.ams3.digitaloceanspaces.com/Entronix-SV_2024-08-09-091637_fqqf.jpg)
Endotronix Receives FDA Premarket Approval of the Cordella™ PA Sensor System for the Treatment of Heart Failure
![](https://svhealth.ams3.digitaloceanspaces.com/EyeBio-Logo.png)
Merck signs $3bn deal for Kate Bingham-backed eye disease biotech
Read More
![](https://svhealth.ams3.digitaloceanspaces.com/logos/EyeBio-Logo.png)
SV Health Investors-created EyeBio to be acquired by MSD for up to $3 billion
![](https://svhealth.ams3.digitaloceanspaces.com/Nanopath__Logo.jpg)
Nanopath Receives $4 Million in Grants from National Institutes of Health and National Science Foundation
![](https://svhealth.ams3.digitaloceanspaces.com/logos/Quralis_Logo_Royal_Blue_RGB-01NOV23.jpg)
QurAlis to Present Data That Show its Splice-Switching ASOs Restore UNC13A Function in ALS and Frontotemporal Dementia
SV investment has resulted in the approval of 24 novel therapeutics
![](https://svhealth.ams3.digitaloceanspaces.com/SV-website-news.jpg)
SV Health Investors bolsters senior biotech team - appoints Nikola Trbovic as Managing Partner and hires Jamil Beg as Partner
![](https://svhealth.ams3.digitaloceanspaces.com/hightop.png)
Hightop Health adds industry veteran to Board of Directors - Seasoned CEO and McLean Hospital Board Chair joins Hightop’s executive leadership
![](https://svhealth.ams3.digitaloceanspaces.com/logos/CarawayTx_rgb_large1.png)
Merck to Acquire Caraway Therapeutics, Inc.
![](https://svhealth.ams3.digitaloceanspaces.com/logos/EyeBio-Logo.png)
EyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal Diseases
![](https://svhealth.ams3.digitaloceanspaces.com/ICGLOGO.jpg)
SV Health Investors partners with HIT Executives Dave Dyell and Marc Hirshfield to Lead Recapitalization of Innovative Consulting Group
SV News
- 13 February 2024Portfolio NewsSudo Biosciences Announces Second Close of Upsized Series B Financing Bringing Total Raised in Round to $147M
- 24 January 2024Portfolio NewsAmphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted protein degraders
- 12 January 2024SV NewsThe deal flow just gets better and better”: how Europe's startups are pushing progress for neurodegenerative diseases
- 3 January 2024Portfolio NewsQurAlis Strengthens Global Presence With Opening of European Headquarters That Includes R&D Manufacturing
- 28 November 2023Portfolio NewsHarness Therapeutics secures additional £4 million funding to pursue physiological upregulation approach to treat neurodegenerative diseases
- 21 November 2023Portfolio NewsDementia Discovery Fund Announces the Acquisition of Caraway Therapeutics by Merck
- 21 November 2023Portfolio NewsMerck to Acquire Caraway Therapeutics, Inc.
- 14 November 2023Portfolio NewsTransposon Announces Interim Results from a Phase 2 Study of TPN-101 for the Treatment of Progressive Supranuclear Palsy to be Presented at the AD/PD™ 2024 International Conference on Alzheimer's and Parkinson's Diseases
- 13 November 2023Portfolio NewsCerevance Doses First Patient in ASCEND Phase 2 Clinical Study of CVN424, a First-in-Class, Non-Dopaminergic Therapy for the Treatment of Parkinson’s Disease
- 6 November 2023Portfolio NewsAviadoBio Announces FDA IND Clearance and Fast Track Designation for AVB-101 for the Treatment of Frontotemporal Dementia with Progranulin (GRN) Mutations
- 18 October 2023Portfolio NewsCumulus Neuroscience to Present Data at CTAD 2023 Annual Meeting
- 10 October 2023Portfolio NewsAviadoBio Announces Initiation of Phase 1/2 Clinical Trial, ASPIRE-FTD, Evaluating AVB-101 in People with Frontotemporal Dementia with GRN Mutations